Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$10M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$163M |
Are Cyclerion Therapeutics Insiders Buying or Selling?
Cyclerion Therapeutics (CYCN) has had no reported insider transactions in the past 90 days. The most recent was Slate Path Capital LP, who sold 357,880 shares at $1.55 on November 21, 2024.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the CYCN AI Score. For government officials trading this stock, see CYCN congressional trading.
Recent Cyclerion Therapeutics Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Slate Path Capital LP | Nov 21, 2024 | Sell | 357,880 | $1.55 | $560,000 |
Frequently Asked Questions: Cyclerion Therapeutics Insider Trading
Cyclerion Therapeutics insiders have not reported any transactions in the past 90 days.
The most recent sale was by Slate Path Capital LP who sold 357,880 shares on November 21, 2024. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Slate Path Capital LP has sold the most CYCN stock in the last 2 years, with a total value of $560,000.
The total value of insider transactions for Cyclerion Therapeutics in the last 2 years is negative, amounting to -$560,000. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
